Exelixis | EXEL - Чистый доход





Чистый доход Изменить Дата
Acadia Pharmaceuticals USD 273.57M 201.79M 2025-12
Agios Pharmaceuticals USD -99.11M 8.93M 2026-03
Akebia Therapeutics USD -12.24M 12.78M 2025-12
Amgen USD 1.82B 486M 2026-03
AstraZeneca USD 3.08B 754M 2026-03
Bayer EUR -3.76B 2.79B 2025-12
BioMarin Pharmaceutical USD 105.53M 152.1M 2026-03
Bristol-Myers Squibb USD 2.68B 1.59B 2026-03
Cytokinetics USD -183.03M 123.15M 2025-12
Eisai JPY 17.18B 7.02B 2025-12
Eli Lilly USD 7.4B 760M 2026-03
Esperion Therapeutics USD 61.83M 93.16M 2025-12
Exelixis USD 244.53M 50.95M 2025-12
Genmab DKK 31M 370M 2025-12
Glaxosmithkline GBP 846.06M 1.87B 2025-12
Incyte USD 303.33M 4.05M 2026-03
Ionis Pharmaceuticals USD -93M 136M 2026-03
MacroGenics USD -14.16M 30.98M 2025-12
Merck USD -4.24B 7.2B 2026-03
Moderna USD -1.34B 517M 2026-03
Nektar Therapeutics USD -36.08M 978K 2025-12
Neurocrine Biosciences USD 153.7M 55.8M 2025-12
Novartis USD 3.16B 747M 2026-03
Pfizer USD -1.65B 5.19B 2025-12
Puma Biotechnology USD 20.32M 24.85M 2024-09
Sanofi EUR -801M 3.6B 2025-12
Takeda JPY 103.64B 115.44B 2025-12
Ultragenyx Pharmaceutical USD -129M 51.41M 2025-12
Xencor USD -6.65M 626K 2025-12